Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma.

Expert Opinion on Drug Discovery
C Lance Cowey, W Kimryn Rathmell

Abstract

BACKGROUND: Renal cell carcinoma is a disease marked by a unique biology which has governed it's long history of poor response to conventional cancer treatments. The discovery of the signaling pathway activated as a result of inappropriate constitutive activation of the hypoxia inducible factors (HIF), transcription factors physiologically and transiently stabilized in response to low oxygen, has provided a primary opportunity to devise treatment strategies to target this oncogenic pathway. OBJECTIVE: A review of the molecular pathogenesis of renal cell cancer as well as molecularly targeted therapies, both those currently available and those in development, will be provided. In addition, trials involving combination or sequential targeted therapy are discussed. METHODS: A detailed review of the literature describing the molecular biology of renal cell cancer and novel therapies was performed and summarized. RESULTS/CONCLUSION: Therapeutics targeting angiogenesis have provided the first class of agents which provide clinical benefit in a large majority of patients and heralded renal cell carcinoma as a solid tumor paradigm for the development of novel therapeutics. Multiple strategies targeting this pathway and now other identi...Continue Reading

References

May 1, 1994·Nature Genetics·J R GnarraF M Duh
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·J G HermanW M Linehan
Oct 1, 1996·Proceedings of the National Academy of Sciences of the United States of America·J R GnarraW M Linehan
Oct 1, 1996·Proceedings of the National Academy of Sciences of the United States of America·O IliopoulosM A Goldberg
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·K IwaiA Pause
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
Jan 27, 2000·The Journal of Urology·R J Motzer, P Russo
May 24, 2000·The Journal of Biological Chemistry·M E CockmanP H Maxwell
Jun 8, 2002·The Journal of Biological Chemistry·Jennifer S IsaacsLeonard M Neckers
Sep 21, 2002·Molecular and Cellular Biology·Christine C HudsonRobert T Abraham
Feb 18, 2003·The Journal of Biological Chemistry·Nianli SangJaime Caro
Feb 21, 2003·Biochemical and Biophysical Research Communications·Hang ChangShankung Lin
Apr 3, 2003·Journal of the National Cancer Institute·Eun-Jin YeoJong-Wan Park
May 3, 2003·Cancer Cell·Nicola J MabjeeshParaskevi Giannakakou
Jun 20, 2003·Lancet·Russell R LonserEdward H Oldfield
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Sep 6, 2003·Cancer Cell·James B BrugarolasWilliam G Kaelin
Oct 28, 2003·Investigational New Drugs·Beverly DruckerRobert Motzer
Dec 24, 2003·PLoS Biology·Keiichi KondoWilliam G Kaelin
Feb 7, 2004·Cancer Biology & Therapy·Gerald W HartNeeraja Sathyamoorthy
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael B AtkinsMatthew L Sherman
Apr 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brian I RiniUNKNOWN Cancer and Leukemia Group B
Dec 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nancy A DawsonArif Hussain
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk StrumbergSiegfried Seeber
Feb 16, 2005·Nature Biotechnology·Miles A FabianDavid J Lockhart
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Herbert I HurwitzFairooz Kabbinavar
Jul 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edwin P M JansenCornelis J H van de Velde
Jul 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hope S RugoGeorge Wilding
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey W ClarkHeinz-Josef Lenz
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthAnthony Greco
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine FaivreEric Raymond
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerBrian I Rini
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark J RatainPeter J O'Dwyer

❮ Previous
Next ❯

Citations

Feb 17, 2009·Current Oncology Reports·C Lance Cowey, W Kimryn Rathmell
Apr 29, 2010·Current Oncology Reports·A Rose Brannon, W Kimryn Rathmell
Nov 30, 2011·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Wani Arjumand, Sarwat Sultana
Jun 12, 2012·Seminars in Nuclear Medicine·Amir H Khandani, W Kimryn Rathmell
Jun 4, 2020·Journal of Cancer Research and Clinical Oncology·Jiang ChangPan Hu
Aug 6, 2014·Molecular Cancer Research : MCR·Hiroaki HaseKazutake Tsujikawa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.